TransCode Therapeutics (NASDAQ:RNAZ) Trading Down 3.4% – Time to Sell?

TransCode Therapeutics Inc. (NASDAQ:RNAZ)’s stock price dropped 3.4% on Friday . The company traded as low as $2.87 and last traded at $2.87. 38,971 shares traded hands during mid-day trading, an increase of 37% from the average daily volume of 28,420 shares. The stock had previously closed at $2.97.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TransCode Therapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

TransCode Therapeutics Stock Performance

The stock has a market capitalization of $3.04 million, a P/E ratio of -0.05 and a beta of 1.24. The business has a 50-day moving average price of $5.78 and a 200 day moving average price of $7.36.

TransCode Therapeutics (NASDAQ:RNAZ) last posted its quarterly earnings data on Friday, August 14th. The company reported ($7.17) earnings per share for the quarter.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.